Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

C9874

Sigma-Aldrich

Potassium clavulanate:cellulose (1:1)

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
51285005
Nomenclature NACRES :
NA.85

Forme

powder or crystals

Spectre d'activité de l'antibiotique

Gram-negative bacteria
Gram-positive bacteria

Mode d’action

enzyme | inhibits

Température de stockage

2-8°C

Application

Clavulanate is used as an inhibitor of bacterial β-lactamase enzymes. It is produced by the fermentation of Streptomyces clavuligerus. It has weak antibacterial activity when used alone but is very active when used with amoxicillin. With Amoxicillin, it is used to treat infections caused by Staph. aureus, Bacteroides fragilis, H. influenza and E. coli.. It has been used to treat acute bacterial sinusitis in children and chronic adenotonsillar hypertrophy.

Actions biochimiques/physiologiques

Clavulanate is a β-lactam antibiotic related to the penicillins. Clavulanic acid competitively and irreversibly inhibits a wide variety of β-lactamases which are commonly found in microorganisms that are resistant to penicillins and cephalosporins. Clavulanate also is a modulator of the central nervous system. It enhances dopamine release in PC12 and SH-SY5Y cells without affecting dopamine synthesis.
Clavulanate is a β-lactamase inhibitor often used to enhance the antibacterial activity of amoxicillin.

Autres remarques

Mixture of potassium clavulanate and cellulose
Keep container tightly closed in a dry and well-ventilated place. Never allow product to get in contact with water during storage.Heat sensitive. Storage class (TRGS 510): Flammable solid hazardous materials.

Pictogrammes

Health hazard

Mention d'avertissement

Danger

Mentions de danger

Classification des risques

Resp. Sens. 1 - Skin Sens. 1

Risques supp

Code de la classe de stockage

13 - Non Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

B Rossi et al.
Antimicrobial agents and chemotherapy, 60(1), 424-430 (2015-11-04)
We investigated the efficacies of cefotaxime (CTX) and amoxicillin (AMX)-clavulanate (CLA) (AMC) against extended-spectrum-β-lactamase (ESBL)-producing Escherichia coli in vitro and in a murine model of urinary tract infection (UTI). MICs, the checkerboard dilution method, and time-kill curves were used to
Ellen R Wald et al.
Pediatrics, 124(1), 9-15 (2009-07-01)
The role of antibiotic therapy in managing acute bacterial sinusitis (ABS) in children is controversial. The purpose of this study was to determine the effectiveness of high-dose amoxicillin/potassium clavulanate in the treatment of children diagnosed with ABS. This was a
Gina Chun Kost et al.
Neuroscience letters, 504(2), 170-175 (2011-10-04)
Clavulanic acid is a CNS-modulating compound with exceptional blood-brain barrier permeability and safety profile. Clavulanic acid has been proposed to have anti-depressant activity and is currently entering Phase IIb clinical trials for the treatment of Major Depressive Disorder (MDD). Studies
A P Sclafani et al.
Pediatrics, 101(4 Pt 1), 675-681 (1998-04-29)
To evaluate the short- and long-term effects of treatment of symptomatic chronic adenotonsillar hypertrophy (CATH) with a 30-day course of amoxicillin/clavulanate potassium (AMOX/CLAV). Children 2 to 16 years of age with obstructive symptoms attributable to CATH, who did not have
Alasdair M Geddes et al.
International journal of antimicrobial agents, 30 Suppl 2, S109-S112 (2007-09-29)
Infections are currently ranked as the leading global burden of disease with respiratory diseases playing the most significant role. Antibiotic resistance remains a serious problem, as it was even 50 years ago. The 1970s saw the introduction of a number

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique